Evidence map›Paper›PMID 37784000›Full record

ArticleJournal of gastrointestinal cancer2024

The Clinical Impact of Change in the C-Reactive Protein/Albumin Ratio in Gastric Cancer Patients Who Receive Curative Treatment.

Toru Aoyama, Yukio Maezawa, Itaru Hashimoto, Kentaro Hara, Keisuke Komori, Kazuki Otani, Keisuke Kazama, Sho Sawazaki, Masakatsu Numata, Shinnosuke Kawahara and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastrointestinal cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Toru AoyamaDepartment of Surgery, Yokohama City University, Yokohama, Japan. t-aoyama@lilac.plala.or.jp.
Yukio Maezawa *Department of Surgery, Yokohama City University, Yokohama, Japan.
Itaru HashimotoDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Kentaro HaraDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Keisuke KomoriDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Kazuki OtaniDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Keisuke KazamaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Sho SawazakiDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Masakatsu NumataDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Shinnosuke KawaharaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Haruhiko ChoDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Junya MoritaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Kenki SegamiDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Mie TanabeDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Norio YukawaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Aya SaitoDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Yasushi RinoDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Takashi OgataDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Takashi OshimaDepartment of Surgery, Yokohama City University, Yokohama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecently, change in the C-reactive protein/albumin ratio (CAR) has become a promising prognostic marker in some malignancies. The aim of the present study was to evaluate the clinical impact of change in the CAR in gastric cancer patients who received curative resection.

methodThe present study included 458 patients who underwent curative treatment for gastric cancer between 2013 and 2017. The prognosis and clinicopathological parameters were compared between patients who showed a high-change in CAR and those who showed a low-change in CAR.

resultsThe OS stratified by each clinical factor was compared using a log-rank test, and a significant difference was observed using a 0.05 change in CAR. When the patient background factors were compared between the high-change (change in CAR ≥ 0.05) and low-change (change in CAR < 0.05) groups, the median age, sex ratio, T factor, and N factor were similar. In the low-change group, the OS rates at 3 and 5 years after surgery were 94.1% and 87.6%, respectively, which amounted to a significant difference from the low-change group, with rates of 83.6 and 77.5% in the high-change group. In the low-change group, the RFS rates at 3 and 5 years after surgery were 90.1% and 85.1%, respectively, while those in the high-change group 77.6 and 75.2%. The univariate and multivariate analyses of factors associated with OS and RFS showed that the change in CAR was a significant prognostic factor.

conclusionsThe change in CAR is a significant risk factor and promising prognostic factor for gastric cancer patients.

Indexed as

C-Reactive ProteinStomach NeoplasmsAdultAgedAged, 80 and overBiomarkers, TumorFemaleGastrectomyHumansMaleMiddle AgedPrognosisRetrospective StudiesSerum AlbuminSurvival RateBiomarkers, TumorC-Reactive ProteinSerum AlbuminC-reactive protein/albumin ratioCurative treatmentGastric cancer

Identifiers

PMID37784000
PMCPMC11096194

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.